NeueHealth Inc

NeueHealth — Q1 2024 Earnings Presentation

11 slides from NeueHealth's earnings presentation, May 8, 2024

  1. Slide 1: NeueHealth First Quarter 2024 Earnings Presentation

    NeueHealth First Quarter 2024 - Earnings Presentation May 8, 2024 Privileged & Confidential | © 2024

  2. Slide 2: Disclaimer

    Disclaimer Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future re

  3. Slide 3: NeueHealth: A Value-Driven Healthcare Company

    NeueHealth: A Value-Driven Healthcare Company A value-driven, consumer-centric care model grounded in strong, ongoing relationships with provider and payor partners and proactive consumer engagement NeueHealth Value-driven care delivery and provider enablement business partnering with leading health

  4. Slide 4: Overview of Q1 2024 Results for Continuing Operations

    Overview of Q1 2024 Results for Continuing Operations Strong Results Through Q1 Position NeueHealth for Continued Success in 2024 Enterprise Metrics ($M) Revenue Gross Margin Adj. Operating Cost Ratio(1) Adjusted EBITDA(2) Key Considerations • Q1 ‘24 Revenue of $245.1 million slightly below expectat

  5. Slide 5: Balance Sheet and Liquidity Highlights

    Balance Sheet and Liquidity Highlights Focused on building a strong foundation for long-term sustainable growth Summary Balance Sheet Q1’24 Key Considerations March 31 March 31 • $256.4 million in total cash and investments, including $143.7 million ($ in thousands) 2024 2023 in regulated entities.

  6. Slide 6: NeueHealth 2024 Outlook

    NeueHealth 2024 Outlook NeueHealth • Revenue of ~$1 Billion • Adjusted Operating Cost Ratio 15% - 16%, excluding corporate costs. Including corporate costs this is expected to be 19% - 20%(1)(2) • Adjusted EBITDA between $15 million and $25 million(1) NeueCare NeueSolutions • 330,000 to 345,000 Year

  7. Slide 7: Appendix

    Appendix

  8. Slide 8: Non-GAAP Reconciliation: Adjusted EBITDA

    Non-GAAP Reconciliation: Adjusted EBITDA Three Months Ended March 31, March 31, ($ in thousands) 2024 2023 Net Loss ($4,177) ($169,461) Loss from discontinued operations 9,865 115,543 EBITDA adjustments from continuing operations Interest expense 2,930 7,787 Income tax (benefit) expense 663 1,259 De

  9. Slide 9: Non-GAAP Reconciliation: Adjusted Operating Cost Ratio

    Non-GAAP Reconciliation: Adjusted Operating Cost Ratio Three Months Ended March 31, March 31, ($ in thousands) 2024 2023 GAAP Operating Cost Ratio 27.3% 26.5% Impact of Share-based compensation expense (7.6)% (11.1)% Adjusted Operating Cost Ratio 19.7% 15.4% 9

  10. Slide 10: Forward-Looking Non-GAAP Measures

    Forward-Looking Non-GAAP Measures This presentation contains Adjusted EBITDA and Adjusted Operating Cost Ratio, which are non-GAAP financial measures. These non-GAAP financial measures are additions, and not substitutes for or superior to the most directly comparable GAAP financial measures, Net Inc

  11. Slide 11: Slide 11

NeueHealth — Q1 2024 Earnings Presentation on 6ix